Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles

Zhu, Guanyin; Lu, Boyao; Qian, Zhiyong; Peng, Qiang

doi:10.1002/med.21767

Cited by 44 publications

(22 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recently published studies, Zhang et al provided a brief summary of the latest developments on the nano-protein interactions between NPs and enzymes of the digestion and initiated an engaging discussion on the possibility of the use of the digestive enzyme corona for the targeted delivery in the colon. 216 The authors described physicochemical properties that are closely linked to the oral absorption of NPs, which include: size, zeta potential and surface molecules, which are greatly affected by the interaction of nano-enzymes and the formation of the enzyme corona. Moreover, it has been shown that the uptake of NPs by epithelial cells is significantly increased after the formation of the enzyme corona.…”

Section: Pharmacokinetic and Toxicological Studies Of Nanoparticles As A Delivery Systemmentioning

confidence: 99%

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Milewska¹,

Niemirowicz-Laskowska²,

Siemiaszko³

et al. 2021

IJN

View full text Add to dashboard Cite

Nanotherapy is a part of nanomedicine that involves nanoparticles as carriers to deliver drugs to target locations. This novel targeting approach has been found to resolve various problems, especially those associated with cancer treatment. In nanotherapy, the carrier plays a crucial role in handling many of the existing challenges, including drug protection before early-stage degradations of active substances, allowing them to reach targeted cells and overcome cell resistance mechanisms. The present review comprises the following sections: the first part presents the introduction of pharmacoeconomics as a branch of healthcare economics, the second part covers various beneficial aspects of the use of nanocarriers for in vitro, in vivo, and pre- and clinical studies, as well as discussion on drug resistance problem and present solutions to overcome it. In the third part, progress in drug manufacturing and optimization of the process of nanoparticle synthesis were discussed. Finally, pharmacokinetic and toxicological properties of nanoformulations due to up-to-date studies were summarized. In this review, the most recent developments in the field of nanotechnology’s economic impact, particularly beneficial applications in medicine were presented. Primarily focus on cancer treatment, but also discussion on other fields of application, which are strongly associated with cancer epidemiology and treatment, was made. In addition, the current limitations of nanomedicine and its huge potential to improve and develop the health care system were presented.

show abstract

Section: Pharmacokinetic and Toxicological Studies Of Nanoparticles As A Delivery Systemmentioning

confidence: 99%

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Milewska¹,

Niemirowicz-Laskowska²,

Siemiaszko³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…The formation of protein corona is affected by many factors, mainly including the physical and chemical properties of nanoparticles and nanoparticles (NPs) exposure concentration. It is found that the traditional oral drug treatment results for inflammatory bowel disease, colon cancer, and other colon diseases are not ideal, but after NPs enzyme corona complex is transported to the colon, after bacteria degrade enzymes, canopy and nanoparticles, its loaded drugs can be released in the colon to achieve targeted treatment of colon diseases [146]. Researchers found that although the targeting of NPs can be promoted by modifying the surface, the results are often disappointing.…”

Section: Discussionmentioning

confidence: 99%

Exosomal targeting and its potential clinical application

Ren

Wang

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Exosomes are extracellular vesicles secreted by a variety of living cells, which have a certain degree of natural targeting as nano-carriers. Almost all exosomes released by cells will eventually enter the blood circulation or be absorbed by other cells. Under the action of content sorting mechanism, some specific surface molecules can be expressed on the surface of exosomes, such as tetraspanins protein and integrin. To some extent, these specific surface molecules can fuse with specific cells, so that exosomes show specific cell natural targeting. In recent years, exosomes have become a drug delivery system with low immunogenicity, high biocompatibility and high efficacy. Nucleic acids, polypeptides, lipids, or small molecule drugs with therapeutic function are organically loaded into exosomes, and then transported to specific types of cells or tissues in vivo, especially tumor tissues, to achieve targeting drug delivery. The natural targeting of exosome has been found and recognized in some studies, but there are still many challenges in effective clinical treatments. The use of the natural targeting of exosomes alone is incapable of accurately transporting the goods loaded to specific sites. Besides, the natural targeting of exosomes is still an open question in disease targeting and efficient gene/chemotherapy combined therapy. Engineering transformation and modification on exosomes can optimize its natural targeting and deliver the goods to a specific location, providing wide use in clinical treatment. This review summarizes the research progress of exosomal natural targeting and transformation strategy of obtained targeting after transformation. The mechanism of natural targeting and obtained targeting after transformation are also reviewed. The potential value of exosomal targeting in clinical application is also discussed. Graphical abstract

show abstract

“…Besides various types of biomolecules existent inside or on the surface of EVs, recent studies have shown that EVs, after entering gastrointestinal tract, blood, or even cell culture media, can readily bind proteins and form a protein corona on the surface. [93,94] Protein corona on nano particles can significantly affect their surface charges and overall sizes, affecting biodistribution and theranostic functions. [95] Hence, it would be essential to consider protein corona when EVs were used for in vivo drug delivery applications.…”

Section: Proteinsmentioning

confidence: 99%

Harnessing the Therapeutic Potential of Extracellular Vesicles for Biomedical Applications Using Multifunctional Magnetic Nanomaterials

Yang

Patel

Rathnam

et al. 2022

Small

View full text Add to dashboard Cite

muscle cells, and stem cells. [5][6][7][8][9][10][11][12] Although initially considered as membrane debris with no biological significance, the crucial roles of EVs in immune surveillance, viral infection, blood coagulation, tissue repair, and stem cell maintenance, have been sequentially identified since 1996. [6,[13][14][15][16][17][18][19] Additionally, biomolecular compositions inside EVs have also been closely associated with the pathology of various kinds of diseases such as cancers, musculoskeletal diseases, as well as degenerative neurological disorders. [20][21][22] As a result of the fundamental role of EVs in mediating cell-to-cell communications and regulating various tissue functions, there has been a critical need to develop novel therapeutics and diagnostics (or theranostics) using EVs and their associated biomolecules. [23] For example, cellfree therapy using EVs derived from mesenchymal stem cells (MSCs) has been exploited and is currently under clinical trials to enhance tissue regeneration after cardiac infarction. [6,7,17,18] Similarly, EVs capable of crossing the bloodbrain barrier (BBB) have been utilized for intranasal delivery of therapeutics for treating central nervous system (CNS) injuries. [24][25][26][27] Moreover, minimally invasive, highly sensitive/accurate diagnosis of cancer metastasis, viral infection, Prion diseases, Alzheimer's disease (AD), and Parkinson's disease (PD), has also been realized by analyzing the biomolecular formulation of EVs extracted from human body fluids. [28,29] Although the potential of using EVs for theranostic applications is enormous, their current clinical translation is still impeded by several critical barriers, which can be attributed mainly to the high heterogeneity of EVs. In general, there are four levels of heterogeneity of EVs, including size, composition, function, and source heterogeneities. [2,30] Specifically, most clinical applications often require a well-defined source of therapeutics. Sizes, compositions, functions, and sources have all been closely associated with the outcome of clinical treatment and diagnostic diseases. [30][31][32][33][34][35][36] Having the ability to isolate a specific population of EVs with well-defined sizes, biomolecular contents, disease-specific biological functions, and biodistributions would be crucial for the clinical application of EVs. Failing to achieve this can lead to compromised therapeutic effects and sometimes even adverse outcomes. For example, the multifaceted roles of EVs have been identified for regulating Extracellular vesicles (e.g., exosomes) carrying various biomolecules (e.g., proteins, lipids, and nucleic acids) have rapidly emerged as promising platforms for many biomedical applications. Despite their enormous potential, their heterogeneity in surfaces and sizes, the high complexity of cargo biomolecules, and the inefficient uptake by recipient cells remain critical barriers for their theranostic applications. To address these critical issues, multifunctional nanomaterials, such as magn...

show abstract

Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles

Cited by 44 publications

References 88 publications

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Exosomal targeting and its potential clinical application

Harnessing the Therapeutic Potential of Extracellular Vesicles for Biomedical Applications Using Multifunctional Magnetic Nanomaterials

Contact Info

Product

Resources

About